rP-Delivery Technology
Upperton’s world leading expertise in biomolecule conjugation of proteins, peptides and drugs to recombinant human albumin has created a highly-flexible delivery platform :
- Production of nano-sized particles from peptides, proteins and other biomolecules
- Nanoparticles are capable of crossing membranes and carrying active drugs into cells
- Unique advantages of the technology include size-control, preservation of molecule’s structural and functional integrity, simplicity and scalability of production process.
- Technology has been demonstrated with recombinant albumin, transferrin, Apolipoprotein A-1, and monoclonal antibodies
More information on rP-nanoTM:
- Proteins, peptides or API’s can be covalently attached to recombinant human albumin using a range of chemistries.
- Once drugs or biomolecules have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties
- Serum half life can be increased from less than a minute to hours or days
- Linking technology has been demonstrated with a wide range of proteins, peptides, monoclonal antibodies and small molecules (API’s).
More information on rP-conjugateTM:
- Upperton’s rP-targetTM technology chemically links monoclonal antibodies to recombinant human albumin or albumin nanoparticles
- Drug loaded albumin molecules or nanoparticles can thus be targeted to specific sites in the body.
- Several drug loaded albumin molecules can be linked to a single monoclonal antibody, increasing delivery efficiency.
- Despite high drug pay-loads being achieved, antibody binding activity is maintained
More information on rP-targetTM:
Print